Replies to post #146843 on Biotech Values

[EYEBUYSTOX]

The reason I have to believe that there will be CRs is that in the last update, the CEO mentioned there were several patients still receiving maintenance therapy of bavituximab. This is only allowed under the trial design if disease has not progressed. All, IMO.

[Thurly]

There is absolutely no reason to believe that PPHM will report CRs in the bavi arm...

Actually, there is: Advanced and Metastatic Breast Cancer. Similar trial protocol, docetaxel vs. docetaxel/bavi arms. 10.9% CRs.

On top of that, the company reported in July that neither treatment arm had triggered and that they did not expect the treatment arms to trigger any time soon.

On top of that, Dr. Garnick stating during the same webcast something like, these are the best results he'd ever seen in X number of years in the business.

The fact that you dismiss these all of these items doesn't equate to there being "no reason to believe" that CRs are possible here.

All these items may turn out to be fluff. Only a select few insiders know for sure.

Almost all the longs I know are now green and, if they manage their risk well, will remain green regardless of the outcome.